Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$15.85 USD
+0.18 (1.15%)
Updated Jun 12, 2024 03:59 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CHGCY 15.85 +0.18(1.15%)
Will CHGCY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHGCY
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for CHGCY
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
Chugai Pharmaceutical Co., Ltd. 2024 Q1 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU